Federal Register / Vol. 90, No. 26 / Monday, February 10, 2025 / Notices 9243 

1Effective December 2, 2022, the Medical 

Marijuana and Cannabidiol Research Expansion 

Act, Public Law 117–215, 136 Stat. 2257 (2022) 

(Marijuana Research Amendments or MRA), 

amended the Controlled Substances Act (CSA) and 

other statutes. Relevant to this matter, the MRA 

redesignated 21 U.S.C. 823(f), cited in the OSC, as 

21 U.S.C. 823(g)(1). Accordingly, this Decision cites 

to the current designation, 21 U.S.C. 823(g)(1), and 

to the MRA-amended CSA throughout. 

2Neither party filed exceptions to the RD. 

3See Gonzales v. Oregon, 546 U.S. 243, 269–71 

(2006); see also OSC, at 2–3. The versions of the 

California authorities cited in this Decision/Order 

were in effect from at least January 2020 through 

June 2022, the time period alleged in the OSC. OSC, 

at 3–8. 

(Authority: Government in the Sunshine Act, 

5 U.S.C. 552b) 

Vicktoria J. Allen, 

Deputy Secretary of the Commission. 

[FR Doc. 2025–02480 Filed 2–6–25; 4:15 pm] 

BILLING CODE 6715–01–P 

FEDERAL RESERVE SYSTEM 

Formations of, Acquisitions by, and 

Mergers of Bank Holding Companies 

The companies listed in this notice 

have applied to the Board for approval, 

pursuant to the Bank Holding Company 

Act of 1956 (12 U.S.C. 1841 et seq.) 

(BHC Act), Regulation Y (12 CFR part 

225), and all other applicable statutes 

and regulations to become a bank 

holding company and/or to acquire the 

assets or the ownership of, control of, or 

the power to vote shares of a bank or 

bank holding company and all of the 

banks and nonbanking companies 

owned by the bank holding company, 

including the companies listed below. 

The public portions of the 

applications listed below, as well as 

other related filings required by the 

Board, if any, are available for 

immediate inspection at the Federal 

Reserve Bank(s) indicated below and at 

the offices of the Board of Governors. 

This information may also be obtained 

on an expedited basis, upon request, by 

contacting the appropriate Federal 

Reserve Bank and from the Board’s 

Freedom of Information Office at 

https://www.federalreserve.gov/foia/ 

request.htm. Interested persons may 

express their views in writing on the 

standards enumerated in the BHC Act 

(12 U.S.C. 1842(c)). 

Comments received are subject to 

public disclosure. In general, comments 

received will be made available without 

change and will not be modified to 

remove personal or business 

information including confidential, 

contact, or other identifying 

information. Comments should not 

include any information such as 

confidential information that would not 

be appropriate for public disclosure. 

Comments regarding each of these 

applications must be received at the 

Reserve Bank indicated or the offices of 

the Board of Governors, Ann E. 

Misback, Secretary of the Board, 20th 

Street and Constitution Avenue NW, 

Washington, DC 20551–0001, not later 

than March 12, 2025. 

A. Federal Reserve Bank of Chicago 

(Colette A. Fried, Assistant Vice 

President) 230 South LaSalle Street, 

Chicago, Illinois 60690–1414. 

Comments can also be sent 

electronically to Comments 

.applications@chi.frb.org: 

1. Bosshard Financial Group, Inc., La 

Crosse, Wisconsin; to merge with 

Bosshard Banco, Ltd., La Crosse, 

Wisconsin, and thereby indirectly 

acquire Intercity State Bank, Schofield, 

Wisconsin, and The First National Bank 

of Bangor, Bangor, Wisconsin. 

Board of Governors of the Federal Reserve 

System. 

Michele Taylor Fennell, 

Associate Secretary of the Board. 

[FR Doc. 2025–02420 Filed 2–7–25; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. 23–5] 

David Bockoff, M.D.; Decision and 

Order 

I. Introduction 

On October 25, 2022, the United 

States Department of Justice (Agency) 

issued an Order to Show Cause and 

Immediate Suspension of Registration 

(collectively, OSC) to David Bockoff, 

M.D., (Respondent) of Beverly Hills, 

California. OSC, at 1, 8. The OSC 

immediately suspended, and proposes 

the revocation of, Respondent’s Drug 

Enforcement Administration (DEA) 

registration, No. BB4591839, ‘‘because 

. . . [Respondent’s] continued 

registration constitutes ‘an imminent 

danger to the public health or safety,’ ’’ 

and ‘‘because . . . [Respondent’s] 

continued registration is inconsistent 

with the public interest, as that term is 

defined in 21 U.S.C. 823[(g)(1)].’’ 1 Id. at 

1 (citing 21 U.S.C. 824(d) and (a)(4)). 

Respondent timely requested a 

hearing. Request for Hearing (November 

4, 2022), at 1; Prehearing Ruling 

(November 30, 2022), at 1. DEA 

Administrative Law Judge (ALJ) Teresa 

A. Wallbaum conducted a four-day 

hearing at the DEA Hearing Facility, 

attended by Respondent and his 

Counsel by video teleconference, on 

January 19, 20, 23, and 24, 2023. 

Recommended Rulings, Findings of 

Fact, Conclusions of Law, and Decision 

of the Administrative Law Judge (RD), at 

2. On May 2, 2023, the ALJ issued her 

RD recommending revocation of 

Respondent’s registration.2 Id. at 43. 

Having thoroughly analyzed the 

record and applicable law, the Agency 

summarizes its findings and 

conclusions: (1) DEA (the Government) 

presented a prima facie case, (2) 

Respondent attempted, but failed, to 

rebut the Government’s prima facie 

case, and (3) substantial and 

uncontroverted record evidence, 

including the testimony of the 

Government’s expert witness, shows 

Respondent’s violations of applicable 

law go to the core of the Controlled 

Substances Act (CSA). Accordingly, the 

Agency will revoke Respondent’s 

registration. Infra Order. 

II. California Physicians’ and Surgeons’ 

Standard of Care 

According to the CSA, ‘‘[e]xcept as 

authorized by this subchapter, it shall 

be unlawful for any person knowingly 

or intentionally . . . to . . . distribute, 

. . . dispense, or possess with intent to 

. . . distribute[ ] or dispense, a 

controlled substance.’’ 21 U.S.C. 

841(a)(1). The CSA’s implementing 

regulations state that a lawful controlled 

substance order or prescription is one 

that is ‘‘issued for a legitimate medical 

purpose by an individual practitioner 

acting in the usual course of his 

professional practice.’’ 21 CFR 

1306.04(a). 

The OSC is addressed to Respondent 

at his registered address in California. 

Therefore, the Agency also evaluates 

Respondent’s actions according to 

California law, including the applicable 

California standard of care.3 Authorities 

in the ‘‘Legal Requirements’’ and 

‘‘Standard of Care’’ sections of the OSC 

give Respondent notice of the bases for 

the OSC’s allegations and, accordingly, 

are the authorities that the Agency is 

using to adjudicate those allegations. 

OSC, at 2–3; infra. 

The first California authority listed in 

the OSC’s ‘‘Legal Requirements’’ section 

is California Health and Safety Code 

§ 11153(a). During the time period 

alleged in the OSC, that California 

provision, similar to the CSA, required 

that a ‘‘prescription for a controlled 

substance shall only be issued for a 

legitimate medical purpose by an 

individual practitioner acting in the 

usual course of his or her professional 

practice.’’ Cal. Health & Safety Code 

§ 11153(a) (West 2023–24); OSC, at 2. 


ddrumheller on DSK120RN23PROD with NOTICES1